Powered by

Regulus Reports Second Quarter 2017 Financial Results and Recent Events

Aug 01, 2017 - PR Newswire
Board and Executive Moves-Financial Results

 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the six months ended June 30, 2017 and recent events.  

"The successful completion of our recent public offering significantly strengthens our financial position through key clinical milestones of our lead programs, RG-012 and RGLS4326," said Jay Hagan, President and Chief Executive Officer of Regulu...